GCM
AXDX

Graham Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Graham Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,400
Closed -$698K – 120
2021
Q1 		$698K Buy
+8,400
New +$852K 0.03% 134

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Graham Capital Management's AXDX Position: Q2 2021 in Review

Graham Capital Management sold out of Accelerate Diagnostics (AXDX) in Q2 2021, closing a stake of 8,400 shares — an estimated $698K sold.

Graham Capital Management first reported a position in AXDX in Q1 2021 and held it in 1 quarter. The position peaked at $698K in Q1 2021. 95 funds tracked by Wall St. Rank hold AXDX as of Q2 2021.

  • Graham Capital Management reported no remaining Accelerate Diagnostics position as of Q2 2021 after selling out during the quarter.
  • Graham Capital Management sold 8,400 Accelerate Diagnostics shares in Q2 2021, an estimated $698K.
  • Graham Capital Management first reported a position in Accelerate Diagnostics in Q1 2021 and held it in 1 quarter.
  • Graham Capital Management's Accelerate Diagnostics position peaked at $698K in Q1 2021.
  • 95 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2021.

Based on Graham Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.